预防急性血栓形成与血管内皮的抗氧化纳米收获器
Yixin Zhong1,2,3, Qiankun Ni3,4,5, Liandi Huang2
1Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital & Basic Medicine Research and Innovation Center of Ministry of Education, Southeast University, Nanjing, China.
Nature nanotechnology
|November 1, 2025
概括
一种新的纳米收集器 (MDCP) 保护内皮细胞免受氧化应激,防止血栓形成而不增加出血风险. 这种方法为当前的抗血小板药物提供了一个有希望的替代品.
科学领域:
- 生物医学工程 生物医学工程
- 血管生物学 血管生物学
- 纳米医学是一种纳米医学.
背景情况:
- 抗血小板药物对于血栓形成治疗至关重要,但有局限性,包括出血风险和疗效.
- 从受损的内皮细胞中过度反应性氧物种 (ROS) 导致血栓形成.
- 目前的治疗方法无法充分解决抗血栓治疗中有效性和安全性的双重挑战.
研究的目的:
- 作为一种潜在的抗血栓策略,研究一种新的ROS-chemotactic nanoscavenger (MDCP).
- 评估MDCP保护血管内皮细胞免受氧化应激和预防血栓形成的能力.
- 通过检查其对出血风险的影响来评估MDCP的安全性.
主要方法:
- 通过交叉连接黑色素和催化酶来合成MDCP.
- 评估了MDCP在预防ROS诱导的内皮细胞亡中的有效性.
- MDCP对血小板激活和血栓形成的影响在体外和体内都进行了评估.
- 将MDCP对出血风险的影响与传统的抗血小板药物进行了比较.
主要成果:
- MDCP治疗抑制了内皮细胞的ROS诱导的亡,从而保持了内皮完整性.
- MDCP防止了受损内皮细胞的原暴露,这是血小板激活的关键触发因素.
- MDCP有效地预防了血小板激活和急性血栓形成.
- 与现有的抗血栓剂相比,MDCP显示出降低了出血风险.
结论:
- MDCP代表了一种新的纳米采集器疗法,通过向血管氧化应激来预防血栓形成.
- 通过保持内皮完整性和避免直接干扰血小板,MDCP提供了一个有前途的抗血小板策略,具有潜在的安全性.
- 这种方法调节了血管氧化还原平衡,解决了当前抗血小板药物的局限性,并为血栓形成管理提供了新的途径.
相关概念视频
Venous Thrombosis III: Interprofessional Care
273
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
273
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Vascular Spasm
3.3K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
3.3K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Venous Thrombosis I: Introduction
335
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
335


